Merck Jessie EnglishMerck KGaA has appointed Dr Jessie English as its new vice president of discovery, transnational innovation platform immuno-oncology.
She will take up her new role on 16 February, when she will lead the discovery team’s efforts in the exploration of disease targets and translating these into patient care.
Dr English joins Merck from the Belfer Institute for Applied Cancer Sciences at Havard Medical School’s Dana-Farber Cancer Institute where she had been head of research since March 2012.
During her two decades of work in oncology and immune-oncology research, she has also served as vice president of kinase biology at ArQule, oncology site lead for external discoveries at Merck Research Laboratories.
Prior to that she held leadership positions at both Pfizer Research and Schering-Plough Research Institute.
Source: PMLive
AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.
Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.
Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.
